Abbott Laboratories $ABT Shares Bought by Ingalls & Snyder LLC

Ingalls & Snyder LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 4.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 262,240 shares of the healthcare product maker’s stock after purchasing an additional 11,861 shares during the quarter. Abbott Laboratories comprises 1.1% of Ingalls & Snyder LLC’s portfolio, making the stock its 15th largest position. Ingalls & Snyder LLC’s holdings in Abbott Laboratories were worth $35,124,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Abbott Laboratories by 1.8% during the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after acquiring an additional 2,977,715 shares during the period. State Street Corp boosted its stake in Abbott Laboratories by 0.9% during the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after purchasing an additional 689,517 shares during the period. Geode Capital Management LLC grew its position in Abbott Laboratories by 3.8% in the 2nd quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after purchasing an additional 1,390,554 shares during the last quarter. Norges Bank acquired a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $3,026,180,000. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Abbott Laboratories by 5.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after buying an additional 821,325 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was bought at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Piper Sandler decreased their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. Daiwa Securities Group decreased their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Evercore lowered their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Leerink Partners reduced their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Finally, BTIG Research decreased their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Trading Down 0.4%

Shares of Abbott Laboratories stock opened at $112.27 on Wednesday. The business has a fifty day simple moving average of $119.12 and a 200-day simple moving average of $126.18. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23. The firm has a market cap of $195.22 billion, a price-to-earnings ratio of 30.18, a price-to-earnings-growth ratio of 1.79 and a beta of 0.75. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the previous year, the business earned $1.34 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, February 13th. Investors of record on Thursday, January 15th were issued a dividend of $0.63 per share. The ex-dividend date was Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s payout ratio is 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.